Terms and Conditions

PLEASE READ THIS AGREEMENT CAREFULLY BEFORE ACCESSING THIS WEBSITE. BY ACCESSING THIS WEBSITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS BELOW. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, YOU MAY NOT ACCESS OR USE THIS WEBSITE.

Wynzora.com and its content are owned by MC2 Therapeutics and licensed to EPI Health through a partnership agreement.

MC2 Therapeutics Ltd
James House
Emlyn Lane
Leatherhead KT22 7EP
United Kingdom
[email protected]
Tel. + 45 5360 6812

For Product Information:
Patients: [email protected].com
Healthcare Providers: [email protected]
1-800-449-4468

EPI Health, LLC
134 Columbus Street
Charleston, South Carolina 29403

USA
[email protected]
Telephone: 843-965-8333

 

The content of the wynzora.com website and the websites of companies affiliated with Wynzora® is protected by applicable national or international law, regulation, and treaty, including but not limited to copyright laws and trademark laws.

MC2 Therapeutics and EPI Health (the “Companies”) are diligently working to ensure that the information provided on this website is accurate and up to date. The Companies do not guarantee the accuracy or completeness of the information provided on this website.

Permission to browse website and limited permission to make copies:
You may browse this website for information and may print copies of its contents for your own use. You must obtain the prior written consent of MC2 Therapeutics and/or EPI Health if you want to incorporate all or some of the contents into your own website or written materials or create “derivative works.” To obtain written permission, please send your written request to [email protected]
and/or [email protected].

Trademarks

The Companies’ names, trademarks, service marks, trade names, logos, slogans, and product names displayed on this website are protected worldwide and may not be used in any way without the prior written consent of MC2 Therapeutics and/or EPI Health.

Cookies

By accessing wynzora.com, data is collected about you that is used to customize and enhance our content and to increase the relevance of ads. If you do not wish to share this data, you should delete cookies and refrain from further use of the website.

The website may contain cookies from third parties.

License

Unless otherwise stated, MC2 Therapeutics Inc. and/or EPI Health own the intellectual property rights for all material on wynzora.com. All intellectual property rights are reserved. You may access this from wynzora.com for your own personal use subjected to restrictions set in these terms and conditions.

You must not:

  • Republish material from wynzora.com
  • Sell, rent, or sub-license material from wynzora.com
  • Reproduce, duplicate or copy material from wynzora.com
  • Redistribute content from wynzora.com

Links

Neither MC2 Therapeutics nor EPI Health has reviewed all of the sites linked to its website and is not responsible for the contents of any such linked site. The inclusion of any link does not imply endorsement, by either Company, of the site. Use of any such linked website is at the user’s own risk.

iFRAMES

Without prior approval and written permission, you may not create frames around our webpages that alter in any way the visual presentation or appearance of our website.

DISCLAIMER OF LIABILITY

The information on this website is provided “as is” and without any warranty or representation of any kind, expressed or implied, including those of merchantability, fitness for a particular purpose, or non-infringement. Neither MC2 Therapeutics nor EPI Health accepts any liability for the accuracy, completeness, or use of this information. The Companies do not assume any obligation to update the documents and information available on the website. The access and use of this website and the content thereof are at the user’s own risk.

Despite the above, reasonable care is being taken to ensure that the content of the website is accurate and up to date. However, the Companies do not make any warranties or representations about accuracy, sequence, timeliness, or completeness of the website content and may discontinue distributing the website without prior notice. The Companies reserve their right to alter, modify, substitute, or delete any content on this site at any time and at their sole discretion.

Information presented on the wynzora.com website is presented solely for informational purposes. The site does not provide you with advice or recommendations of any kind and should never substitute advice provided by a doctor or other qualified healthcare professionals.

In no event shall the Companies or their affiliates be liable for any injury or any direct, indirect, incidental, consequential or punitive damages, lost profits, lost data, or any other loss or damage arising out of your access to, or inability to access, this website or from your reliance on any information provided herein even if the Companies or their affiliate has been informed of the possibility thereof. This limitation includes damages or any viruses, which may affect your computer.

RESERVATION OF RIGHTS

We reserve the right to request that you remove all links or any particular link to our website. You consent to immediately remove all links to our website upon request. We also reserve the right to amend these terms and conditions and its linking policy at any time. By continuously linking to our website, you agree to be bound to and follow these linking terms and conditions.

REMOVAL OF LINKS FROM OUR WEBSITE

If you find any link on our website that is offensive for any reason, you are free to contact us. We will consider requests to remove links, but we are not obligated to do so or to respond to you directly.

arrow

Indication and Use

Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.

Important Safety Information

  • Wynzora Cream is for topical use only.
  • Patients should not use more than 100g of Wynzora Cream per week.
  • Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally.
  • Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site.
  • Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks.
  • Patients should discontinue use once the plaque psoriasis is under control.
  • Patients should not use with occlusive dressings.
  • Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene.
  • Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma.
  • It is not known whether Wynzora Cream may harm your unborn baby.
  • Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola.
  • It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. 2. US Department of Health and Human Services. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 41st ed. US Government Publishing Office; 2021. https://www.fda.gov/media/71474/download. Accessed April 21, 2021. 3. Wynzora® Cream [package insert]. MC2 Therapeutics; 2020. 4. MC2 Therapeutics. PAD™ Technology. https://padcream.com/. Accessed February 19, 2021.